Titlebook: Alternative Approaches to Human Blood Resources in Clinical Practice; Proceedings of the T C. Th. Smit Sibinga,P. C. Das,J. C. Fratantoni C

mortality

書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice影響因子(影響力)




書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice影響因子(影響力)學(xué)科排名




書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice網(wǎng)絡(luò)公開度




書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice被引頻次




書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice被引頻次學(xué)科排名




書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice年度引用




書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice年度引用學(xué)科排名




書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice讀者反饋




書目名稱Alternative Approaches to Human Blood Resources in Clinical Practice讀者反饋學(xué)科排名

整理

What should Trigger a Transfusion?e similar transfusion demands or transfusion rates. The local practice may be defined by a number of factors, such as the local consensus on the postoperative haemoglobin level or platelet transfusion level, the preferences of opinion leaders in the local clinical community [7], the availability of

含鐵

The Efficacy of Technologies to Minimise Peri-Operative Allogeneic Transfusionty of methods intended to minimise peri-operative transfusion. These include pharmacological agents (aprotinin, desmopressin (DDAVP), tranexamic acid (TXA), epsilon aminocaproic acid (EACA) and erythropoietin (EPO)), pre-operative autologous donation (PAD), acute normovolemic haemodilution (ANH), an

harrow

Evidence-Based Transfusion Medicine or the Need to Evaluate Clinical Outcome decisions. In practice it means an integration of individual clinical expertise with the best available external clinical evidence from systemic research. EBM will never replace clinical skills, clinical judgement and clinical experience. In the concept of EBM a clinical problem will be turned into

攝取

Confidential

MODE

Recombinant Human Erythropoietin — could it be used in a Better Way?pean Union, and Canada since 1993, 1994, and 1996 respectively, and for perisurgical adjuvant therapy without ABD in Canada and the US since 1966. This paper is intended to provide a framework for clinicians who will have the options of administering EPO therapy to patients undergoing surgery, and t

coltish

Muffle

The Development of Synthocytes?, a Novel Platelet Substituteomposed of microcapsules of human serum albumin (HSA) to which human fibrinogen is immobilised. The product is manufactured using virally inactivated human blood derived proteins and is formulated as a sterile pyrogen free lyophilised preparation. The potential advantages of Synthocytes. over platel

conjunctiva